Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.71 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.71 |
| ▸ | OSBP | P22059 | 1/20 | 0.71 |
| ▸ | RORC | P51449 | 1/20 | 0.71 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.71 |
| ▸ | GRIN1 | Q05586 | 15/20 | 0.66 |
| ▸ | GRIN2B | Q13224 | 15/20 | 0.66 |
| ▸ | GRIN2A | Q12879 | 13/20 | 0.65 |
| ▸ | POLA1 | P09884 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103515 | 0.90 | USP2 (0.74) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL4961477 | 0.90 | GRIN1 (0.80) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2185461 | 0.90 | USP2 (0.74) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL932623 | 0.90 | USP2 (0.74) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL5935410 | 0.90 | GRIN1 (0.80) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL4244982 | 0.90 | GRIN1 (0.71) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL10943687 | 0.89 | USP2 (0.71) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL8930167 | 0.89 | USP2 (0.71) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL18529717 | 0.89 | USP2 (0.71) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL10887781 | 0.89 | USP2 (0.71) | USP2CYP46A1LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109312332-A | Isolation and analysis of fetal DNA from extravillous trophoblast cells obtained from the endocervical canal | 韦恩州立大学 | 2019-02-05 | — | — | CN | disclosed |
| CN-107667288-A | Spectral analysis of microorganisms | 英国质谱公司 | 2018-02-06 | — | — | CN | disclosed |
| CN-107635478-A | The fabric analysis carried out by mass spectrum or ion mobility spectrometry | 英国质谱公司 | 2018-01-26 | — | — | CN | disclosed |
| US-20120052125-A1 | Cholesteryl Sulfate-Containing Composition As A Haemostatic | DR. SUWELACK SKIN & HEALTH CARE AG (DE) | 2012-03-01 | — | — | US | disclosed |
| EP-2315605-A1 | CHOLESTERYL SULFATE-CONTAINING COMPOSITION AS A HAEMOSTATIC | Dr. Suwelack Skin & Health Care AG (DE) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010015378-A1 | CHOLESTERYL SULFATE-CONTAINING COMPOSITION AS A HAEMOSTATIC | DR. SUWELACK SKIN & HEALTH CARE AG (DE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052125-A1 | Cholesteryl Sulfate-Containing Composition As A Haemostatic | CETP, LIPA, APOB | USP2 1242/4885CYP46A1 9/4885LMNA 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.